Abstract Plant species of the genus Cannabis L. are predominantly recognized for their cannabinoids, which have garnered significant attention due to their bioactive properties. However, Cannabis also produces a diverse array of bioactive compounds with promising pharmacological potential that remain underexplored. This review focuses primarily on phytochemicals derived from Cannabis sativa L. subspecies, including both its drug-type and fiber-type varieties, which are the most widely cultivated and studied within the genus. Among these, nitrogen-containing compounds such as spermidine alkaloids exhibit neuroprotective and anti-aging properties, while hydroxycinnamic acids and hydroxycinnamic acid amides, including N-trans-caffeoyltyramine and N-trans-feruloyltyramine, have demonstrated notable antioxidant and anti-inflammatory activities. Additionally, Cannabis species are a valuable source of unique stilbenes,...

Abstract Cannabis is increasingly used for managing chronic pain, despite the low quality and inconsistency of most evidence from randomized controlled trials and the divergent expert opinions and guidelines issued by academic societies. In this perspective piece, we suggest a way forward. The clinical trials have focused on traditional chronic pain outcomes (such as pain severity and interference, as well as physical and emotional functioning). However, qualitative studies suggest that many individuals perceive cannabis as beneficial not because it directly reduces pain but because it alters their psychological responses to it and improves other important outcomes, such as role and social functioning, sleep quality,...

Abstract Cannabis sativa L. is a phytochemically rich plant with therapeutic potential across various clinical domains, including pain, inflammation, and neurological disorders. Among its constituents, terpenes are gaining recognition for their capacity to modulate the pathophysiological processes underlying chronic pain syndromes. Traditionally valued for their aromatic qualities, terpenes such as myrcene, β-caryophyllene (BCP), limonene, pinene, linalool, and humulene have demonstrated a broad spectrum of biological activities. Beyond their observable analgesic, anti-inflammatory, and anxiolytic outcomes, these compounds exert their actions through distinct molecular mechanisms. These include the activation of cannabinoid receptor type 2 (CB2), the modulation of transient receptor potential (TRP) and adenosine receptors, and the...

Abstract Background While numerous studies have indicated acute neurocognitive changes following the administration of Δ9-tetrahydrocannabinol (THC; the psychoactive component of cannabis), the standardised neuropsychological tests most sensitive to THC are yet to be identified. As such, this systematic review analysed scientific evidence (since 2000) on the effects of THC on standardised neuropsychological test measures. Methods This review was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies were eligible for inclusion if they utilised a between or within-subjects design in testing for differences in standardised neuropsychological test performance following the consumption of THC. Results/discussion Sufficient data were identified to examine 8...

Please use this link to access this publication. ABSTRACT Purpose The purpose of this literature review was to assess and evaluate the neurophysiological and visual effects of cannabis, nicotine, and e-cigarettes on patients with traumatic brain injury (TBI). Methods In this review, a literature search was performed using PubMed and Google Scholar resources. In addition, a literature search within cited references was also performed for this review. A total of seventy-two(72) publications as referenced were used for this review. Discussion This literature review is intended to address the neurophysiological and visual impairments of patients with TBI through a systematic review to identify the side...

Abstract Despite medicinal cannabis gaining popularity for managing symptoms in cancer patients, a knowledge gap exists in patient-provider communication crucial for monitoring outcomes, optimizing dosing, and educating healthcare providers to integrate cannabis into treatment plans. Our goal is to understand communication dynamics, identify gaps, and pave the way for effective cannabis communication for individuals living with cancer (PLWC). We searched PubMed, CINAHL, and EBSCO for articles published between 2013 and July 2023, capturing the key concepts of cannabis use in cancer patients and their communication with healthcare providers in oncology settings. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guided the review....

Abstract Hemp (Cannabis sativa L.) is a versatile crop that can be processed to obtain different products with multiple applications. Its seeds are a well-documented ancient source of proteins, fibers and fats, all of which possess high nutritional value. Additionally, metabolites such as flavones and phenols are present in the seeds, contributing to their antioxidant properties. Due to hemp seeds’ distinctive nutritional profile, the interest in exploring the potential use in food and nutraceuticals is growing, and they can be considered an interesting and promising alternative resource for human and animal feeding. Omics studies on hemp seeds and their by-products are also being developed, and...

Abstract Purpose To summarise the extent and type of evidence in relation to adverse events (AEs) associated with the use of cannabis-based products (CBP) in people living with cancer. Methods The Joanna Briggs Institute (JBI) methodology for scoping reviews was applied. A search was performed in MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCOhost), Scopus, Web of Science Core Collections and AMED (Ovid) from their inception to 7 May 2023. Primary studies reporting AEs associated with any form of natural or synthetic CBP use in any cancer care setting and location were included. Results One hundred fifty-two studies were included, with the most prevalent being randomised...

Please use this link to access this publication. Abstract Treatment demand for Cannabis Use Disorder (CUD) has increased in the past decade in almost all European countries, and CUD is currently the most common reason for first-time drug-related treatment admission in the European Union. Even though several therapeutic approaches have been shown to benefit individuals with CUD, there is a lack of knowledge regarding factors associated with effective therapy and the underlying mechanisms of change among individuals with CUD presenting for treatment. The aim of the present paper was to review current knowledge on factors that have been shown to contribute to positive outcomes...

Abstract Objective To assess biological factors associated with anhedonia in depression and amotivation in cannabis use (PROSPERO: CRD42023422438). Method A systematic review was conducted of 8 electronic databases. Inclusion criteria included original research studies that investigated the association of biological factors or behavioral tasks with depression combined with concepts of anhedonia or cannabis combined with concepts of amotivation including apathy. Results The review included 44 articles that evaluated biological factors associated with anhedonia in depression and 2 articles that evaluated biological factors associated with amotivation in cannabis use. Overall, anhedonia was operationalized as loss of anticipatory pleasure or consummatory pleasure using a range of...